Related Experiment Video
Updated: Apr 16, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Using Xenopus tissue cultures for the study of myasthenia gravis pathogenesis
Hwee Li Yeo1, Jorain Yu Ni Lim1, Yuki Fukami2
1Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
Abstract:
Myasthenia gravis (MG), the most common autoimmune disease of neuromuscular junction (NMJ), is heterogeneous in terms of pathophysiology, which is determined by the pathogenic antigen of autoantibodies targeting to synaptic proteins at the NMJs. Currently, patients suspected with MG are routinely screened for the presence of autoantibodies against acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) using a cell-based assay (CBA) that involves the expression of target synaptic membrane protein in heterologous cell lines. However, some autoantibodies may only show reactivity for binding to densely clustered AChR in the physiological conformation, while AChR clustering is known to involve signaling events orchestrated by over a dozen of postsynaptic proteins. To improve the existing serological diagnosis of MG, this study explored the possibility of using the well-established Xenopus primary culture system as a novel CBA for MG. Here, by examining the pathogenic effects of four MG human plasma samples, we found that the samples from both seropositive and seronegative MG patients effectively induced the disassembly of aneural AChR clusters in cultured Xenopus muscle cells, as well as the nerve-induced AChR clusters in the nerve-muscle co-cultures. Importantly, the disassembly of AChR clusters was spatio-temporally correlated to the disappearance of actin depolymerizing factor (ADF)/cofilin, an actin regulator involved in AChR trafficking and clustering. Taken together, this study develops a reliable CBA using Xenopus primary cultures for screening the pathogenicity of human MG plasma samples, and providing a platform for investigating the pathogenic mechanisms underlying the endocytic trafficking and degradation of AChRs at NMJs in MG patients.
Insights
This study introduces a novel Xenopus cell-based assay (CBA) for diagnosing myasthenia gravis (MG). The assay effectively detects pathogenic autoantibodies in MG patient plasma, improving diagnostic capabilities for this neuromuscular junction disorder.
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Myasthenia gravis (MG) is a heterogeneous autoimmune neuromuscular junction (NMJ) disorder.
- Current diagnosis relies on detecting autoantibodies against acetylcholine receptor (AChR) or muscle-specific kinase (MuSK).
- Existing assays may miss autoantibodies reactive to clustered AChR conformations.
Purpose of the Study:
- To develop and validate a novel cell-based assay (CBA) for myasthenia gravis (MG) diagnosis using Xenopus primary cultures.
- To investigate the pathogenic effects of MG patient plasma on acetylcholine receptor (AChR) clusters.
- To explore the role of actin depolymerizing factor (ADF)/cofilin in MG-induced AChR disassembly.
Main Methods:
- Utilized Xenopus primary muscle cell cultures and nerve-muscle co-cultures.
- Examined the effects of human MG plasma samples on AChR clusters.
- Assessed the spatio-temporal correlation between AChR cluster disassembly and ADF/cofilin levels.
Main Results:
- MG patient plasma samples induced disassembly of both aneural and nerve-induced AChR clusters in Xenopus cultures.
- AChR cluster disassembly was correlated with the depletion of actin depolymerizing factor (ADF)/cofilin.
- The novel Xenopus CBA demonstrated reliability in screening MG plasma pathogenicity.
Conclusions:
- Xenopus primary cultures provide a reliable platform for a novel cell-based assay (CBA) for myasthenia gravis (MG).
- This assay can screen the pathogenicity of MG patient plasma, aiding in diagnosis.
- The findings offer a new model for studying AChR trafficking and degradation mechanisms in MG.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

